Key Development On August 20, 2026, global healthcare leader Abbott Laboratories (NYSE: ABT) formally announced a $670 million comprehensive settlement... Read more
Category: Uncategorized
Breakthrough in Personalized Oncology: Moderna and Merck’s Tailored mRNA Cancer Vaccine Intismeran Cuts Melanoma Recurrence and Metastasis in Landmark Phase 3 Trial – Moderna Shares Surge 160%
Key Development On August 19, 2026, Moderna (NASDAQ: MRNA) and Merck & Co. (NYSE: MRK) announced positive interim results from... Read more
CNS Patent Defense & Market Exclusivity: SK Biopharmaceuticals Reaches Landmark Patent Settlement with MSN Laboratories to Protect U.S. Exclusivity for Anti-Epileptic Blockbuster Xcopri® (Cenobamate) Beyond 2032
Key Development On August 19, 2026, South Korean biopharmaceutical leader SK Biopharmaceuticals (KRX: 326030) formally concluded its first patent litigation... Read more
Ultrarare Genetic Disease Milestone: FDA Approves Regeneron’s Pasatru® (Garetosmab) for Fibrodysplasia Ossificans Progressiva (FOP) – Delivering Up to 94% Reduction in New Heterotopic Bone Lesions
Key Development Following more than a decade of translational R&D, Regeneron Pharmaceuticals (NASDAQ: REGN) has secured landmark regulatory approval from... Read more
Health Supplement Advertising Compliance: Vietnam Food Safety Authority Mandates Urgent Hanoi Health Department Inspection into DK-Betics Gold for Misleading Curative Claims and Physician Imagery
Key Development On the evening of August 19, 2026, the Vietnam Food Safety Authority (VFA) under the Ministry of Health... Read more
Digital Health Marketing Enforcement: Vietnam Food Safety Authority Directs Hanoi Department of Health to Audit Misleading Advertising for DK-Betics Gold and Non Alco Lozenges
Key Development The Vietnam Food Safety Authority (VFA) under the Ministry of Health has officially issued an urgent regulatory directive... Read more
Global Infectious Disease Licensing: Chugai Grants GSK Exclusive Worldwide License for Investigational Anti-Dengue Antibody AID351
Key Development Tokyo-headquartered biopharmaceutical enterprise Chugai Pharmaceutical Co., Ltd. (TYO: 4519)—a member of the Roche Group—has officially entered into an... Read more
Targeting Undruggable Ion Channels: Eli Lilly and OmniAb Enter Global Research Collaboration and License Agreement Valued Up to $370 Million for Next-Generation Antibody Therapeutics
Key Development Global biopharmaceutical leader Eli Lilly and Company (NYSE: LLY) has formally executed a global collaboration and license agreement... Read more
Rare Skeletal Disease M&A: BioMarin Acquires Alesta Therapeutics for Up to $490 Million to Challenge AstraZeneca’s Hypophosphatasia Franchise with Oral Asset ALE1
Key Development Rare disease biopharmaceutical leader BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) has entered into a definitive agreement to acquire clinical-stage... Read more









